Why did NWRN.SW stock drop today?

NWRN.SW stock fell **8.33%** intraday mainly due to technical profit-taking after a strong run-up. Indicators show overbought RSI **85.30** and mixed volume. No single major news item is confirmed; watch trial updates and tomorrow’s volume for confirmation.

What are the key support and resistance levels for NWRN.SW stock?

Immediate support sits at **CHF19.00–CHF19.50** and short-term resistance at **CHF22.75** (Bollinger middle). A close below CHF19.00 could signal deeper correction, while a rebound above CHF22.75 would favour trend continuation.

How does Meyka AI view NWRN.SW stock?

Meyka AI rates NWRN.SW with a score out of 100: **71.16 (B+) — BUY**. The grade balances earnings strength and growth against some valuation and DCF flags. This is informational and not financial advice.

What price targets and forecast should holders expect for NWRN.SW stock?

Meyka AI's forecast projects **CHF22.82** (1 month), **CHF31.86** (3 months) and **CHF20.93** (12 months). These imply upside of about **15.25%** to the 1‑month target from today’s **CHF19.80**. Forecasts are model-based and not guarantees.

CH Stocks

NWRN.SW stock down 8.33% intraday to CHF19.80 on 29 Jan 2026: Watch support

ByDanny Kontos January 29, 2026

NWRN.SW stock fell 8.33% intraday to CHF19.80 on 29 Jan 2026, marking a sharp retracement from last session’s CHF21.60 close. The drop came with 116,981 shares traded and a day range between CHF19.24 and CHF20.20. Traders are treating today as a technical correction after an extended run higher: momentum indicators show overbought conditions and volume remains mixed. We break down why price fell, the fundamentals behind Newron Pharmaceuticals S.p.A. (NWRN.SW) on the SIX in Switzerland, and what to watch next.